Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Zhejiang Medicine In-Licenses Novel Antibiotic from TaiGen

publication date: Jun 25, 2012
Zhejiang Medicine Company has in-licensed China rights to manufacture and commercialize a broad-spectrum antibiotic from TaiGen Biotechnology of Taiwan. ZMC will pay $8 million upfront for the license. Nemonoxacin is a novel non-fluorinated quinolone antibiotic, currently completing a Phase III clinical trial for community acquired pneumonia in China and Taiwan. TaiGen expects to file for SFDA approval of the antibiotic in early 2013. More details....

Stock Symbol: (SHA: 600216)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital